The Experts below are selected from a list of 49593 Experts worldwide ranked by ideXlab platform

Yvonne Paterson - One of the best experts on this subject based on the ideXlab platform.

  • Two lisTeria monocyTogenes vaccine vecTors ThaT express differenT molecular forms of human papilloma virus 16 hpv 16 e7 induce qualiTaTively differenT T Cell immuniTy ThaT correlaTes wiTh Their abiliTy To induce regression of esTablished Tumors immorTalized by hpv 16
    Journal of Immunology, 2001
    Co-Authors: George R Gunn, Abba Zubair, Christian Peters, Zhenkun Pan, Yvonne Paterson
    Abstract:

    Two recombinanT LisTeria monocyTogenes (rLm) sTrains were produced ThaT secreTe The human papilloma virus-16 (HPV-16) E7 proTein expressed in HPV-16-associaTed cervical cancer Cells. One, Lm-E7, expresses and secreTes E7 proTein, whereas a second, Lm-LLO-E7, secreTes E7 as a fusion proTein joined To a nonhemolyTic lisTeriolysin O (LLO). Lm-LLO-E7, buT noT Lm-E7, induces The regression of The E7-expressing Tumor, TC-1, esTablished in syngeneic C57BL/6 mice. BoTh recombinanT E7-expressing rLm vaccines induce measurable anTi-E7 CTL responses ThaT sTain posiTively for H-2D(b) E7 TeTramers. DepleTion of The CD8+ T Cell subseT before TreaTmenT abrogaTes The abiliTy of Lm-LLO-E7 To impacT on Tumor growTh. In addiTion, The rLm sTrains induce markedly differenT CD4+ T Cell subseTs. DepleTion of The CD4+ T Cell subseT considerably reduces The abiliTy of Lm-LLO-E7 To eliminaTe esTablished TC-1 Tumors. Surprisingly, The reverse is The case for Lm-E7, which becomes an effecTive anTi-Tumor immunoTherapeuTic in mice lacking This T Cell subseT. Ab-mediaTed depleTion of TGF-beTa and CD25+ Cells improves The effecTiveness of Lm-E7 TreaTmenT, suggesTing ThaT TGF-beTa and CD25+ Cells are in parT responsible for This suppressive response. CD4+ T Cells from mice immunized wiTh Lm-E7 are capable of suppressing The abiliTy of Lm-LLO-E7 To induce The regression of TC-1 when Transferred To Tumor-bearing mice. These sTudies demonsTraTe The complexiTy of L. monocyTogenes-mediaTed Tumor immunoTherapy TargeTing The human Tumor Ag, HPV-16 E7.

  • Two lisTeria monocyTogenes vaccine vecTors ThaT express differenT molecular forms of human papilloma virus 16 hpv 16 e7 induce qualiTaTively differenT T Cell immuniTy ThaT correlaTes wiTh Their abiliTy To induce regression of esTablished Tumors immorTalized by hpv 16
    Journal of Immunology, 2001
    Co-Authors: George R Gunn, Abba Zubair, Christian Peters, Zhenkun Pan, Yvonne Paterson
    Abstract:

    Two recombinanT LisTeria monocyTogenes (rLm) sTrains were produced ThaT secreTe The human papilloma virus-16 (HPV-16) E7 proTein expressed in HPV-16-associaTed cervical cancer Cells. One, Lm-E7, expresses and secreTes E7 proTein, whereas a second, Lm-LLO-E7, secreTes E7 as a fusion proTein joined To a nonhemolyTic lisTeriolysin O (LLO). Lm-LLO-E7, buT noT Lm-E7, induces The regression of The E7-expressing Tumor, TC-1, esTablished in syngeneic C57BL/6 mice. BoTh recombinanT E7-expressing rLm vaccines induce measurable anTi-E7 CTL responses ThaT sTain posiTively for H-2D b E7 TeTramers. DepleTion of The CD8 + T Cell subseT before TreaTmenT abrogaTes The abiliTy of Lm-LLO-E7 To impacT on Tumor growTh. In addiTion, The rLm sTrains induce markedly differenT CD4 + T Cell subseTs. DepleTion of The CD4 + T Cell subseT considerably reduces The abiliTy of Lm-LLO-E7 To eliminaTe esTablished TC-1 Tumors. Surprisingly, The reverse is The case for Lm-E7, which becomes an effecTive anTi-Tumor immunoTherapeuTic in mice lacking This T Cell subseT. Ab-mediaTed depleTion of TGF-β and CD25 + Cells improves The effecTiveness of Lm-E7 TreaTmenT, suggesTing ThaT TGF-β and CD25 + Cells are in parT responsible for This suppressive response. CD4 + T Cells from mice immunized wiTh Lm-E7 are capable of suppressing The abiliTy of Lm-LLO-E7 To induce The regression of TC-1 when Transferred To Tumor-bearing mice. These sTudies demonsTraTe The complexiTy of L. monocyTogenes -mediaTed Tumor immunoTherapy TargeTing The human Tumor Ag, HPV-16 E7.

George R Gunn - One of the best experts on this subject based on the ideXlab platform.

  • Two lisTeria monocyTogenes vaccine vecTors ThaT express differenT molecular forms of human papilloma virus 16 hpv 16 e7 induce qualiTaTively differenT T Cell immuniTy ThaT correlaTes wiTh Their abiliTy To induce regression of esTablished Tumors immorTalized by hpv 16
    Journal of Immunology, 2001
    Co-Authors: George R Gunn, Abba Zubair, Christian Peters, Zhenkun Pan, Yvonne Paterson
    Abstract:

    Two recombinanT LisTeria monocyTogenes (rLm) sTrains were produced ThaT secreTe The human papilloma virus-16 (HPV-16) E7 proTein expressed in HPV-16-associaTed cervical cancer Cells. One, Lm-E7, expresses and secreTes E7 proTein, whereas a second, Lm-LLO-E7, secreTes E7 as a fusion proTein joined To a nonhemolyTic lisTeriolysin O (LLO). Lm-LLO-E7, buT noT Lm-E7, induces The regression of The E7-expressing Tumor, TC-1, esTablished in syngeneic C57BL/6 mice. BoTh recombinanT E7-expressing rLm vaccines induce measurable anTi-E7 CTL responses ThaT sTain posiTively for H-2D(b) E7 TeTramers. DepleTion of The CD8+ T Cell subseT before TreaTmenT abrogaTes The abiliTy of Lm-LLO-E7 To impacT on Tumor growTh. In addiTion, The rLm sTrains induce markedly differenT CD4+ T Cell subseTs. DepleTion of The CD4+ T Cell subseT considerably reduces The abiliTy of Lm-LLO-E7 To eliminaTe esTablished TC-1 Tumors. Surprisingly, The reverse is The case for Lm-E7, which becomes an effecTive anTi-Tumor immunoTherapeuTic in mice lacking This T Cell subseT. Ab-mediaTed depleTion of TGF-beTa and CD25+ Cells improves The effecTiveness of Lm-E7 TreaTmenT, suggesTing ThaT TGF-beTa and CD25+ Cells are in parT responsible for This suppressive response. CD4+ T Cells from mice immunized wiTh Lm-E7 are capable of suppressing The abiliTy of Lm-LLO-E7 To induce The regression of TC-1 when Transferred To Tumor-bearing mice. These sTudies demonsTraTe The complexiTy of L. monocyTogenes-mediaTed Tumor immunoTherapy TargeTing The human Tumor Ag, HPV-16 E7.

  • Two lisTeria monocyTogenes vaccine vecTors ThaT express differenT molecular forms of human papilloma virus 16 hpv 16 e7 induce qualiTaTively differenT T Cell immuniTy ThaT correlaTes wiTh Their abiliTy To induce regression of esTablished Tumors immorTalized by hpv 16
    Journal of Immunology, 2001
    Co-Authors: George R Gunn, Abba Zubair, Christian Peters, Zhenkun Pan, Yvonne Paterson
    Abstract:

    Two recombinanT LisTeria monocyTogenes (rLm) sTrains were produced ThaT secreTe The human papilloma virus-16 (HPV-16) E7 proTein expressed in HPV-16-associaTed cervical cancer Cells. One, Lm-E7, expresses and secreTes E7 proTein, whereas a second, Lm-LLO-E7, secreTes E7 as a fusion proTein joined To a nonhemolyTic lisTeriolysin O (LLO). Lm-LLO-E7, buT noT Lm-E7, induces The regression of The E7-expressing Tumor, TC-1, esTablished in syngeneic C57BL/6 mice. BoTh recombinanT E7-expressing rLm vaccines induce measurable anTi-E7 CTL responses ThaT sTain posiTively for H-2D b E7 TeTramers. DepleTion of The CD8 + T Cell subseT before TreaTmenT abrogaTes The abiliTy of Lm-LLO-E7 To impacT on Tumor growTh. In addiTion, The rLm sTrains induce markedly differenT CD4 + T Cell subseTs. DepleTion of The CD4 + T Cell subseT considerably reduces The abiliTy of Lm-LLO-E7 To eliminaTe esTablished TC-1 Tumors. Surprisingly, The reverse is The case for Lm-E7, which becomes an effecTive anTi-Tumor immunoTherapeuTic in mice lacking This T Cell subseT. Ab-mediaTed depleTion of TGF-β and CD25 + Cells improves The effecTiveness of Lm-E7 TreaTmenT, suggesTing ThaT TGF-β and CD25 + Cells are in parT responsible for This suppressive response. CD4 + T Cells from mice immunized wiTh Lm-E7 are capable of suppressing The abiliTy of Lm-LLO-E7 To induce The regression of TC-1 when Transferred To Tumor-bearing mice. These sTudies demonsTraTe The complexiTy of L. monocyTogenes -mediaTed Tumor immunoTherapy TargeTing The human Tumor Ag, HPV-16 E7.

Zhenkun Pan - One of the best experts on this subject based on the ideXlab platform.

  • Two lisTeria monocyTogenes vaccine vecTors ThaT express differenT molecular forms of human papilloma virus 16 hpv 16 e7 induce qualiTaTively differenT T Cell immuniTy ThaT correlaTes wiTh Their abiliTy To induce regression of esTablished Tumors immorTalized by hpv 16
    Journal of Immunology, 2001
    Co-Authors: George R Gunn, Abba Zubair, Christian Peters, Zhenkun Pan, Yvonne Paterson
    Abstract:

    Two recombinanT LisTeria monocyTogenes (rLm) sTrains were produced ThaT secreTe The human papilloma virus-16 (HPV-16) E7 proTein expressed in HPV-16-associaTed cervical cancer Cells. One, Lm-E7, expresses and secreTes E7 proTein, whereas a second, Lm-LLO-E7, secreTes E7 as a fusion proTein joined To a nonhemolyTic lisTeriolysin O (LLO). Lm-LLO-E7, buT noT Lm-E7, induces The regression of The E7-expressing Tumor, TC-1, esTablished in syngeneic C57BL/6 mice. BoTh recombinanT E7-expressing rLm vaccines induce measurable anTi-E7 CTL responses ThaT sTain posiTively for H-2D(b) E7 TeTramers. DepleTion of The CD8+ T Cell subseT before TreaTmenT abrogaTes The abiliTy of Lm-LLO-E7 To impacT on Tumor growTh. In addiTion, The rLm sTrains induce markedly differenT CD4+ T Cell subseTs. DepleTion of The CD4+ T Cell subseT considerably reduces The abiliTy of Lm-LLO-E7 To eliminaTe esTablished TC-1 Tumors. Surprisingly, The reverse is The case for Lm-E7, which becomes an effecTive anTi-Tumor immunoTherapeuTic in mice lacking This T Cell subseT. Ab-mediaTed depleTion of TGF-beTa and CD25+ Cells improves The effecTiveness of Lm-E7 TreaTmenT, suggesTing ThaT TGF-beTa and CD25+ Cells are in parT responsible for This suppressive response. CD4+ T Cells from mice immunized wiTh Lm-E7 are capable of suppressing The abiliTy of Lm-LLO-E7 To induce The regression of TC-1 when Transferred To Tumor-bearing mice. These sTudies demonsTraTe The complexiTy of L. monocyTogenes-mediaTed Tumor immunoTherapy TargeTing The human Tumor Ag, HPV-16 E7.

  • Two lisTeria monocyTogenes vaccine vecTors ThaT express differenT molecular forms of human papilloma virus 16 hpv 16 e7 induce qualiTaTively differenT T Cell immuniTy ThaT correlaTes wiTh Their abiliTy To induce regression of esTablished Tumors immorTalized by hpv 16
    Journal of Immunology, 2001
    Co-Authors: George R Gunn, Abba Zubair, Christian Peters, Zhenkun Pan, Yvonne Paterson
    Abstract:

    Two recombinanT LisTeria monocyTogenes (rLm) sTrains were produced ThaT secreTe The human papilloma virus-16 (HPV-16) E7 proTein expressed in HPV-16-associaTed cervical cancer Cells. One, Lm-E7, expresses and secreTes E7 proTein, whereas a second, Lm-LLO-E7, secreTes E7 as a fusion proTein joined To a nonhemolyTic lisTeriolysin O (LLO). Lm-LLO-E7, buT noT Lm-E7, induces The regression of The E7-expressing Tumor, TC-1, esTablished in syngeneic C57BL/6 mice. BoTh recombinanT E7-expressing rLm vaccines induce measurable anTi-E7 CTL responses ThaT sTain posiTively for H-2D b E7 TeTramers. DepleTion of The CD8 + T Cell subseT before TreaTmenT abrogaTes The abiliTy of Lm-LLO-E7 To impacT on Tumor growTh. In addiTion, The rLm sTrains induce markedly differenT CD4 + T Cell subseTs. DepleTion of The CD4 + T Cell subseT considerably reduces The abiliTy of Lm-LLO-E7 To eliminaTe esTablished TC-1 Tumors. Surprisingly, The reverse is The case for Lm-E7, which becomes an effecTive anTi-Tumor immunoTherapeuTic in mice lacking This T Cell subseT. Ab-mediaTed depleTion of TGF-β and CD25 + Cells improves The effecTiveness of Lm-E7 TreaTmenT, suggesTing ThaT TGF-β and CD25 + Cells are in parT responsible for This suppressive response. CD4 + T Cells from mice immunized wiTh Lm-E7 are capable of suppressing The abiliTy of Lm-LLO-E7 To induce The regression of TC-1 when Transferred To Tumor-bearing mice. These sTudies demonsTraTe The complexiTy of L. monocyTogenes -mediaTed Tumor immunoTherapy TargeTing The human Tumor Ag, HPV-16 E7.

Christian Peters - One of the best experts on this subject based on the ideXlab platform.

  • Two lisTeria monocyTogenes vaccine vecTors ThaT express differenT molecular forms of human papilloma virus 16 hpv 16 e7 induce qualiTaTively differenT T Cell immuniTy ThaT correlaTes wiTh Their abiliTy To induce regression of esTablished Tumors immorTalized by hpv 16
    Journal of Immunology, 2001
    Co-Authors: George R Gunn, Abba Zubair, Christian Peters, Zhenkun Pan, Yvonne Paterson
    Abstract:

    Two recombinanT LisTeria monocyTogenes (rLm) sTrains were produced ThaT secreTe The human papilloma virus-16 (HPV-16) E7 proTein expressed in HPV-16-associaTed cervical cancer Cells. One, Lm-E7, expresses and secreTes E7 proTein, whereas a second, Lm-LLO-E7, secreTes E7 as a fusion proTein joined To a nonhemolyTic lisTeriolysin O (LLO). Lm-LLO-E7, buT noT Lm-E7, induces The regression of The E7-expressing Tumor, TC-1, esTablished in syngeneic C57BL/6 mice. BoTh recombinanT E7-expressing rLm vaccines induce measurable anTi-E7 CTL responses ThaT sTain posiTively for H-2D(b) E7 TeTramers. DepleTion of The CD8+ T Cell subseT before TreaTmenT abrogaTes The abiliTy of Lm-LLO-E7 To impacT on Tumor growTh. In addiTion, The rLm sTrains induce markedly differenT CD4+ T Cell subseTs. DepleTion of The CD4+ T Cell subseT considerably reduces The abiliTy of Lm-LLO-E7 To eliminaTe esTablished TC-1 Tumors. Surprisingly, The reverse is The case for Lm-E7, which becomes an effecTive anTi-Tumor immunoTherapeuTic in mice lacking This T Cell subseT. Ab-mediaTed depleTion of TGF-beTa and CD25+ Cells improves The effecTiveness of Lm-E7 TreaTmenT, suggesTing ThaT TGF-beTa and CD25+ Cells are in parT responsible for This suppressive response. CD4+ T Cells from mice immunized wiTh Lm-E7 are capable of suppressing The abiliTy of Lm-LLO-E7 To induce The regression of TC-1 when Transferred To Tumor-bearing mice. These sTudies demonsTraTe The complexiTy of L. monocyTogenes-mediaTed Tumor immunoTherapy TargeTing The human Tumor Ag, HPV-16 E7.

  • Two lisTeria monocyTogenes vaccine vecTors ThaT express differenT molecular forms of human papilloma virus 16 hpv 16 e7 induce qualiTaTively differenT T Cell immuniTy ThaT correlaTes wiTh Their abiliTy To induce regression of esTablished Tumors immorTalized by hpv 16
    Journal of Immunology, 2001
    Co-Authors: George R Gunn, Abba Zubair, Christian Peters, Zhenkun Pan, Yvonne Paterson
    Abstract:

    Two recombinanT LisTeria monocyTogenes (rLm) sTrains were produced ThaT secreTe The human papilloma virus-16 (HPV-16) E7 proTein expressed in HPV-16-associaTed cervical cancer Cells. One, Lm-E7, expresses and secreTes E7 proTein, whereas a second, Lm-LLO-E7, secreTes E7 as a fusion proTein joined To a nonhemolyTic lisTeriolysin O (LLO). Lm-LLO-E7, buT noT Lm-E7, induces The regression of The E7-expressing Tumor, TC-1, esTablished in syngeneic C57BL/6 mice. BoTh recombinanT E7-expressing rLm vaccines induce measurable anTi-E7 CTL responses ThaT sTain posiTively for H-2D b E7 TeTramers. DepleTion of The CD8 + T Cell subseT before TreaTmenT abrogaTes The abiliTy of Lm-LLO-E7 To impacT on Tumor growTh. In addiTion, The rLm sTrains induce markedly differenT CD4 + T Cell subseTs. DepleTion of The CD4 + T Cell subseT considerably reduces The abiliTy of Lm-LLO-E7 To eliminaTe esTablished TC-1 Tumors. Surprisingly, The reverse is The case for Lm-E7, which becomes an effecTive anTi-Tumor immunoTherapeuTic in mice lacking This T Cell subseT. Ab-mediaTed depleTion of TGF-β and CD25 + Cells improves The effecTiveness of Lm-E7 TreaTmenT, suggesTing ThaT TGF-β and CD25 + Cells are in parT responsible for This suppressive response. CD4 + T Cells from mice immunized wiTh Lm-E7 are capable of suppressing The abiliTy of Lm-LLO-E7 To induce The regression of TC-1 when Transferred To Tumor-bearing mice. These sTudies demonsTraTe The complexiTy of L. monocyTogenes -mediaTed Tumor immunoTherapy TargeTing The human Tumor Ag, HPV-16 E7.

Abba Zubair - One of the best experts on this subject based on the ideXlab platform.

  • Two lisTeria monocyTogenes vaccine vecTors ThaT express differenT molecular forms of human papilloma virus 16 hpv 16 e7 induce qualiTaTively differenT T Cell immuniTy ThaT correlaTes wiTh Their abiliTy To induce regression of esTablished Tumors immorTalized by hpv 16
    Journal of Immunology, 2001
    Co-Authors: George R Gunn, Abba Zubair, Christian Peters, Zhenkun Pan, Yvonne Paterson
    Abstract:

    Two recombinanT LisTeria monocyTogenes (rLm) sTrains were produced ThaT secreTe The human papilloma virus-16 (HPV-16) E7 proTein expressed in HPV-16-associaTed cervical cancer Cells. One, Lm-E7, expresses and secreTes E7 proTein, whereas a second, Lm-LLO-E7, secreTes E7 as a fusion proTein joined To a nonhemolyTic lisTeriolysin O (LLO). Lm-LLO-E7, buT noT Lm-E7, induces The regression of The E7-expressing Tumor, TC-1, esTablished in syngeneic C57BL/6 mice. BoTh recombinanT E7-expressing rLm vaccines induce measurable anTi-E7 CTL responses ThaT sTain posiTively for H-2D(b) E7 TeTramers. DepleTion of The CD8+ T Cell subseT before TreaTmenT abrogaTes The abiliTy of Lm-LLO-E7 To impacT on Tumor growTh. In addiTion, The rLm sTrains induce markedly differenT CD4+ T Cell subseTs. DepleTion of The CD4+ T Cell subseT considerably reduces The abiliTy of Lm-LLO-E7 To eliminaTe esTablished TC-1 Tumors. Surprisingly, The reverse is The case for Lm-E7, which becomes an effecTive anTi-Tumor immunoTherapeuTic in mice lacking This T Cell subseT. Ab-mediaTed depleTion of TGF-beTa and CD25+ Cells improves The effecTiveness of Lm-E7 TreaTmenT, suggesTing ThaT TGF-beTa and CD25+ Cells are in parT responsible for This suppressive response. CD4+ T Cells from mice immunized wiTh Lm-E7 are capable of suppressing The abiliTy of Lm-LLO-E7 To induce The regression of TC-1 when Transferred To Tumor-bearing mice. These sTudies demonsTraTe The complexiTy of L. monocyTogenes-mediaTed Tumor immunoTherapy TargeTing The human Tumor Ag, HPV-16 E7.

  • Two lisTeria monocyTogenes vaccine vecTors ThaT express differenT molecular forms of human papilloma virus 16 hpv 16 e7 induce qualiTaTively differenT T Cell immuniTy ThaT correlaTes wiTh Their abiliTy To induce regression of esTablished Tumors immorTalized by hpv 16
    Journal of Immunology, 2001
    Co-Authors: George R Gunn, Abba Zubair, Christian Peters, Zhenkun Pan, Yvonne Paterson
    Abstract:

    Two recombinanT LisTeria monocyTogenes (rLm) sTrains were produced ThaT secreTe The human papilloma virus-16 (HPV-16) E7 proTein expressed in HPV-16-associaTed cervical cancer Cells. One, Lm-E7, expresses and secreTes E7 proTein, whereas a second, Lm-LLO-E7, secreTes E7 as a fusion proTein joined To a nonhemolyTic lisTeriolysin O (LLO). Lm-LLO-E7, buT noT Lm-E7, induces The regression of The E7-expressing Tumor, TC-1, esTablished in syngeneic C57BL/6 mice. BoTh recombinanT E7-expressing rLm vaccines induce measurable anTi-E7 CTL responses ThaT sTain posiTively for H-2D b E7 TeTramers. DepleTion of The CD8 + T Cell subseT before TreaTmenT abrogaTes The abiliTy of Lm-LLO-E7 To impacT on Tumor growTh. In addiTion, The rLm sTrains induce markedly differenT CD4 + T Cell subseTs. DepleTion of The CD4 + T Cell subseT considerably reduces The abiliTy of Lm-LLO-E7 To eliminaTe esTablished TC-1 Tumors. Surprisingly, The reverse is The case for Lm-E7, which becomes an effecTive anTi-Tumor immunoTherapeuTic in mice lacking This T Cell subseT. Ab-mediaTed depleTion of TGF-β and CD25 + Cells improves The effecTiveness of Lm-E7 TreaTmenT, suggesTing ThaT TGF-β and CD25 + Cells are in parT responsible for This suppressive response. CD4 + T Cells from mice immunized wiTh Lm-E7 are capable of suppressing The abiliTy of Lm-LLO-E7 To induce The regression of TC-1 when Transferred To Tumor-bearing mice. These sTudies demonsTraTe The complexiTy of L. monocyTogenes -mediaTed Tumor immunoTherapy TargeTing The human Tumor Ag, HPV-16 E7.